Bax Is Present as a High Molecular Weight Oligomer/Complex in the Mitochondrial Membrane of Apoptotic Cells*

Bruno AntonssonDagger, Sylvie Montessuit, Belen Sanchez§, and Jean-Claude Martinou§

From the Serono Pharmaceutical Research Institute, Serono International S.A., 14 chemin des Aulx, CH-1228 Plan-les Ouates, Geneva, Switzerland

Received for publication, November 30, 2000, and in revised form, December 27, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Bax is a Bcl-2 family protein with proapoptotic activity, which has been shown to trigger cytochrome c release from mitochondria both in vitro and in vivo. In control HeLa cells, Bax is present in the cytosol and weakly associated with mitochondria as a monomer with an apparent molecular mass of 20,000 Da. After treatment of the HeLa cells with the apoptosis inducer staurosporine or UV irradiation, Bax associated with mitochondria is present as two large molecular weight oligomers/complexes of 96,000 and 260,000 Da, which are integrated into the mitochondrial membrane. Bcl-2 prevents Bax oligomerization and insertion into the mitochondrial membrane. The outer mitochondrial membrane protein voltage-dependent anion channel and the inner mitochondrial membrane protein adenosine nucleotide translocator do not coelute with the large molecular weight Bax oligomers/complexes on gel filtration. Bax oligomerization appears to be required for its proapoptotic activity, and the Bax oligomer/complex might constitute the structural entirety of the cytochrome c-conducting channel in the outer mitochondrial membrane.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Apoptosis is mediated through two major pathways, the death receptor pathway and the mitochondrial pathway (1). The mitochondrial pathway is controlled and regulated by the Bcl-2 family of proteins (2-4). This protein family can be divided into antiapoptotic (Bcl-2, Bcl-XL, Bcl-w, Mcl-1, A1) and proapoptotic (Bax, Bak, Bok/Mtd, Bcl-Xs, Bid, Bad, Bik/Nbk, Bim, Blk) members (5-7). Although the overall amino acid sequence homology between the family members is relatively low, they contain highly conserved domains, referred to as Bcl-2 homology domains (BH1 to -4). The activity of these proteins appears to be regulated, at least partly, by formation of homo- and heterocomplexes (8-13). The conserved BH domains are involved in these interactions. In the proapoptotic proteins, Bax and Bak, the BH3 domain is essential for complex formation as well as for their "killing" effect (4, 14-17). The hydrophobic C-terminal domain present in some of the proteins has been implicated in targeting the proteins to intracellular membranes (11, 18). Thus, many members of the family including Bcl-2, Bcl-XL, Bak, and Bax are acting at the level of mitochondria.

It now appears clear that mitochondria have an important function in at least some apoptotic signaling cascades (3, 19- 20). Following a death stimulus, many proteins from the mitochondrial intramembrane space, including cytochrome c, adenylate kinase, Smac/DIABLO, procaspases, and apoptosis-inducing factor, have been reported to be released into the cytosol (21-26). The release of cytochrome c has been shown to be a fast process, depleting the mitochondria of cytochrome c within a few minutes (27). In the cytosol, cytochrome c forms a complex with Apaf-1, dATP, and procaspase 9 (28). The complex formation leads to caspase 9 activation followed by downstream activation of other caspases, ultimately leading to cell death. Mounting evidence points to Bax and other proapoptotic family members as the central regulators of the release of proteins from the mitochondrial intramembrane space. Overexpression of Bax in cells or the addition of purified recombinant Bax directly to isolated mitochondria triggers the release of cytochrome c (29-32). However, the mechanism through which Bax triggers the permeability of the outer mitochondrial membrane is unclear.

The three-dimensional solution structure of the full-length Bax protein has recently been solved by NMR (33). The Bax structure shows a high similarity to the overall conformation of the two other Bcl-2 family proteins for which structural information is available, the antiapoptotic protein Bcl-XL and the BH3 domain-only protein Bid (34-36). The proteins contain central hydrophobic helices (alpha 5 and alpha 6) surrounded by amphipathic helices. Of the three proteins, the Bax structure is the only one that contains the C-terminal hydrophobic domain. This domain forms a helix (alpha 9) that protects the BH3-containing hydrophobic cleft on the protein. The structures of the Bcl-2 proteins are reminiscent of diphtheria toxin and the colicins A and E1. These toxins are pore-forming proteins that function as membrane channels that allow passage of ions or small polypeptides. Bax and other Bcl-2 family proteins have been shown to possess channel-forming activity in artificial membranes (37-40).

We have shown that in contrast to oligomeric Bax, monomeric recombinant Bax cannot form channels in liposomes nor trigger cytochrome c release from isolated mitochondria (41). Recently, Bax tetramers were shown to form a channel large enough to allow the release of cytochrome c from liposomes (42). Here we show that, in cultured cells exposed to the apoptosis inducer staurosporine or UV irradiation, Bax forms oligomers, which possibly form complexes with yet unidentified mitochondrial membrane proteins. The Bax oligomers are found inserted into the mitochondrial membrane. Moreover, we show that in the presence of Bcl-2, Bax oligomer formation and insertion into the mitochondrial membrane is inhibited.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The Superdex 200 (16/60) column was from Amersham Pharmacia Biotech, and 14% polyacrylamide gels and 10% NuPage gels were from Novex (San Diego, CA). CHAPS1 was from Roche Molecular Biochemicals, and Triton X-100 was from Fluka. Polyclonal anti-Bax antibodies were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY), monoclonal anti-Bax antibodies were from R & D Systems (Minneapolis, MN), monoclonal anti-Bcl-2 antibodies were from Genosys (Cambridge, UK), polyclonal anti-Bcl-XL antibodies were from Transduction Laboratories (Lexington, KY), monoclonal anti-Bak antibodies were from Oncogene Research Products (Boston, MA), monoclonal anti-VDAC and polyclonal anti-catalase antibodies were from Calbiochem, monoclonal anti-HA antibodies were from Babco (Richmond, CA), monoclonal anti-Myc and polyclonal anti-His antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), monoclonal anti-COX antibodies were from Molecular Probes, Inc. (Eugene, OR), monoclonal anti-Golgi 58-kDa protein antibodies were from Sigma, and the monoclonal anti-calnexin and anti-Hsp70 antibodies were from Affinity Bioreagents (Golden, CO). The polyclonal rabbit anti-ANT antibody was a kind gift from Prof. Theo Wallimann (43).

Cell Culture-- HEK cells, HeLa cells, and a stable HeLa cell line constitutively overexpressing Bcl-2 (HeLa-Bcl-2) (44) were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 µg/ml streptomycin, and 50 IU/ml penicillin. Apoptosis was induced by culturing the cells in medium containing 1 µM staurosporine for 16 h; alternatively, the cells were UV irradiated (280 mJ cm-2) and subsequently cultured for 16 h. Control cells were cultured in the absence of staurosporine or without UV irradiation. At the end of the treatment, the cells were harvested in phosphate-buffered saline containing 1 mM EDTA, recovered by centrifugation at 750 × g for 10 min, washed, and suspended in mitochondrial buffer (MB) (210 mM manitol, 70 mM sucrose, 1 mM EDTA, 10 mM Hepes-NaOH, pH 7.5).

Isolation of Mitochondria-- The cells suspended in MB supplemented with complete protease inhibitor mixture (Roche Molecular Biochemicals) were disrupted by passage through a 25G1 0.5 × 25 needle. The sample was passed through the needle five times and subsequently centrifuged at 2000 × g for 3 min. The supernatant was saved, and the pellet was resuspended in MB. The breakage procedure was repeated four times. The combined supernatants were centrifuged at 2000 × g for 3 min to remove nuclei and unbroken cells. The supernatant was subsequently centrifuged at 13,000 × g for 10 min. This supernatant was kept and centrifuged at 100,000 × g for 30 min to give the cytosolic cell fraction. The pellet fraction, corresponding to the mitochondrial fraction, was suspended in MB and recentrifuged at 13,000 × g for 10 min. Alternatively, the first 13,000 × g mitochondrial pellet was suspended in 4 ml of MB, and 2-ml portions were layered on top of a discontinuous sucrose gradient consisting of 20 ml of 1.2 M sucrose, 10 mM Hepes-NaOH, 1 mM EDTA, pH 7.5, on top of 17 ml of 1.6 M sucrose, 10 mM Hepes-NaOH, 1 mM EDTA, pH 7.5. The sample was centrifuged at 27,000 rpm in a Beckman SW28 rotor for 2 h at 4 °C. Mitochondria were recovered at the interface of 1.2 and 1.6 M sucrose and washed in MB. All manipulations were carried out at 4 °C.

Treatment of Isolated Mitochondria with Recombinant Caspase 8-Cleaved Bid-- Isolated mitochondria (3 mg/ml) suspended in 1 ml of KCl buffer (15 mM Hepes-NaOH, 125 mM KCl, 4 mM MgCl2, 5 mM NaH2PO4, 0.5 mM EGTA, 5 mM succinate, pH 7.5) were incubated with 50 nM recombinant caspase 8-cleaved Bid for 30 min at 30 °C. At the end of the incubation, the sample was centrifuged at 13,000 × g for 10 min, and the mitochondria were washed with MB buffer.

Preparation of Mitochondrial Extracts-- The washed mitochondrial fraction was suspended in MB containing 2% CHAPS or 2% Triton X-100, incubated on ice for 1 h, sonicated, and centrifuged at 100,000 × g for 30 min. The supernatant corresponds to the solubilized mitochondrial fraction. Protein concentrations were determined using the Bio-Rad protein assay kit.

Sodium Carbonate Extraction of the Mitochondria-- The mitochondrial pellet was suspended in 0.1 M Na2CO3, pH 12, to a final protein concentration of 3 mg/ml and incubated on ice for 20 min. At the end of the incubation, the sample was centrifuged at 100,000 × g for 1 h. The supernatant, which contains nonmembrane-integrated proteins, was saved, and CHAPS was added to a final concentration of 2%. The pellet was suspended in MB containing 2% CHAPS, incubated on ice for 1 h, sonicated, and centrifuged at 100,000 × g for 30 min. The supernatant, which contains solubilized integral membrane proteins, was saved.

Gel Filtration Analyses-- Gel filtrations were performed at 4 °C on a Superdex 200 (16/60) column equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, pH 7.5, and run at a flow rate of 1 ml/min. When Triton extracts were analyzed, CHAPS was replaced by 2% Triton X-100. The column was calibrated with gel filtration standard proteins from Amersham Pharmacia Biotech giving the following elution volumes: thyroglobulin (669,000 Da), 49.9 ml; ferritin (440,000 Da), 55.9 ml; catalase (232,000 Da), 65.5 ml; BSA (67,000 Da), 77.5 ml; ovalbumin (43,000 Da), 83.2 ml; chymotrypsinogen A (25,000 Da), 92.9 ml; ribonuclease A (13,700 Da), 97.4 ml. The void volume of the column was determined by blue Sepharose that eluted at 43.3 ml. A 500-µl sample was loaded onto the column, and the eluate was monitored at 280 nm. After 20 min elution (20 ml), fractions of 2 ml were collected, and aliquots from the fractions were analyzed by Western blotting. The samples were separated on 14% SDS-PAGE under reducing conditions and transferred to polyvinylidene difluoride membranes. The proteins were detected with the specific antibodies as indicated in the figures, and the blots were developed with the ECL system from Amersham Pharmacia Biotech.

Transfection of HEK Cells with Tagged Bax-- Bax was tagged with His, HA, and Myc at the N terminus, and the constructs were cloned into the pC1 vector (Stratagene). HEK cells were then transfected with the three different Bax constructs (Fugene6) (Roche Molecular Biochemicals). The transfection efficiency was between 50 and 60%. 100 µM ZVAD was added 60 min prior to the addition of 1.6 µg of each of the Bax plasmids, and the cells were cultured for 16 h. At the end of the incubation, the cells were harvested, and mitochondria were isolated by differential centrifugation as described above.

Bax Activation, Cross-linking, and Immunoprecipitation-- Mitochondria isolated from transfected HEK cells corresponding to 0.5 mg of mitochondrial protein was incubated with 1 µM caspase 8-cleaved Bid in KCl buffer (15 mM Hepes-NaOH, 125 mM KCl, 4 mM MgCl2, 5 mM NaH2PO4, 0.5 mM EGTA, 5 mM succinate, pH 7.5) for 15 min at 30 °C. At the end of the incubation, the mitochondria were recovered by centrifugation and resuspended in 400 µl of MB containing 1 mM EGTA. The cross-linkers bis-(sulfosuccinimidyl)suberate (Pierce) and disuccinimidyl suberate (Pierce) were added to final concentrations of 2 mM, and the sample was incubated for 30 min at room temperature. The reaction was stopped by the addition of Tris-HCl, pH 8.0, to a final concentration of 20 mM and subsequent incubation for 15 min at room temperature. The mitochondria were recovered by centrifugation and solubilized by incubation in radioimmune precipitation buffer (19 mM Tris-HCl, 140 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 1% sodium deoxycholate) for 30 min at 4 °C. The sample was centrifuged at 12,000 × g for 10 min, and the supernatant was treated with 50 µl of protein G-Sepharose for 3 h at 4 °C. Protein G-Sepharose was removed by centrifugation, and 4 µg of anti-His antibody and 50 µl of protein G-Sepharose were added and incubated on rotation for 16 h at 4 °C. Protein G-Sepharose was recovered by centrifugation and washed four times with 400 µl of radioimmune precipitation buffer. The washed Sepharose was suspended in sample buffer, and the samples were analyzed on 10% NuPage gels in a Mops running buffer system (Novex). Proteins were transferred to nitrocellulose membranes and analyzed by Western blot with four different antibodies, anti-HA, anti-Myc, anti-Bax, and anti-VDAL.

Cytosolic samples were centrifuged at 100,000 × g for 5 min and then treated with cross-linker and analyzed as above.

Recombinant Proteins-- Full-length Bax with a His tag at the N terminus was expressed in Escherichia coli and purified as previously described (45). Oligomerization was induced by disrupting the bacteria in buffer containing 1% Triton X-100. During the purification, Triton was exchanged for 1% octyl glucoside. The purified protein was stored in 25 mM Hepes-NaOH, 0.2 mM DTT, 1% octyl glucoside, 30% glycerol, pH 7.5, at -80 °C.

Full-length Bid with a His tag at the N terminus was expressed in E. coli and purified as previously described (46). The purified Bid was stored in 25 mM Tris-HCl, 0.1 mM DTT, 30% glycerol, pH 7.5, at -80 °C. Caspase 8-cleaved Bid was generated by mixing 200 µl of Bid (12.4 mg/ml) with 200 µl of caspase cleavage buffer (50 mM Hepes-NaOH, 10 mM DTT, 100 mM NaCl, 10% sucrose, pH 7.5) and 1 µl of caspase 8 (3 mg/ml), and the sample was incubated for 2 h at 20 °C. Over 95% of Bid was cleaved as estimated by SDS-PAGE. Cleaved Bid was separated from caspase 8 by binding to Ni2+-nitrilotriacetic acid-agarose; step-eluted by 100 mM imidazole; dialyzed into 25 mM Tris-HCl, 0.1 mM DTT, 30% glycerol, pH 7.5; and stored at -80 °C.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Bax in Extracts from Control and Apoptotic HeLa Cells-- Cultured HeLa cells have been used to study the quaternary structure of Bax in apoptotic cells. Apoptosis was induced by culturing the cells in the presence of 1 µM staurosporine for 16 h or by UV irradiation. Consistent with published results, in untreated HeLa cells, Bax was found both in the cytosol and associated with the mitochondria (Fig. 1). In apoptotic cells, Bax almost completely disappeared from the cytosol. Although a small increase in Bax associated with the mitochondria was seen in the apoptotic cells, this does not fully account for the decreased cytosolic Bax concentration (Fig. 1), suggesting that cytosolic Bax that is not translocated to the mitochondria is eliminated in apoptotic cells, possibly through proteolysis (47).



View larger version (42K):
[in this window]
[in a new window]
 
Fig. 1.   Bax in cytosol and mitochondria from control and apoptotic HeLa cells. The cells were broken in MB buffer, and the cytosol and mitochondrial fractions were isolated as described. The cytosolic (Cyt) and the mitochondrial (Mit) samples (1 µg of total protein) were analyzed on SDS-PAGE and Western blot with anti-Bax antibodies.

Bax Quaternary Structure in Triton X-100 Mitochondrial Extracts from Control and Apoptotic HeLa Cells-- To study the quaternary structure of Bax associated with mitochondria from control and apoptotic HeLa cells, mitochondrial proteins were extracted with 2% Triton X-100 as described under "Materials and Methods." The soluble mitochondrial extracts were analyzed on gel filtration, and the fractions from the column were analyzed by Western blot with an anti-Bax antibody. Gel filtration separates molecules according to the Stokes radius and gives an estimate of their molecular weights and thus of their quaternary structure. Bax extracted from either control or apoptotic HeLa cell mitochondria eluted as a single peak at fractions 20-24, corresponding to a molecular mass of 260,000 Da (Fig. 2). Monomeric Bax was found neither in control nor apoptotic mitochondrial extract. Furthermore, analysis of other mitochondrial membrane proteins that have been suggested to interact with Bax, including Bak, Bcl-XL, and VDAC, all coeluted with Bax as high molecular weight complexes in fractions 20-24. Again, no difference was observed between mitochondrial extracts from control and apoptotic cells (Fig. 2). However, the mitochondrial membrane protein Cox IV eluted with a main peak in fractions 28-30 and a minor peak in fractions 22-24. The void volume of the column was at fraction 12. 



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Analysis of Triton X-100 mitochondrial extract from control and apoptotic HeLa cells by gel filtration on Superdex 200. Mitochondria were isolated and treated with 2% Triton X-100. Solubilized proteins were recovered by centrifugation at 100,000 × g for 30 min. 500 µl of the soluble fraction containing 2 mg of protein was loaded on a Superdex 200 column (16/60) equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) Triton X-100, pH 7.5, and eluted at a flow rate of 1 ml/min. Fractions of 2 ml were collected, and every second fraction was analyzed by SDS-PAGE and Western blot with antibodies against, Bax, Bak, Bcl-XL, VDAC, and Cox IV.

Triton X-100 has been reported to induce dimerization of Bax and other Bcl-2 family members (48). In a previous study, we reported that Triton X-100 was able to trigger oligomerization of soluble monomeric Bax (41). Therefore, Triton might have induced the oligomerization of Bax and possibly other proteins extracted from the mitochondrial membrane, masking any differences in protein quaternary structure between control and apoptotic cells. Previous studies on the ability of various detergents to trigger Bax oligomerization showed that in contrast to Triton X-100 and octyl glucoside, CHAPS had no effect on Bax quaternary structure (41). Therefore, we examined whether CHAPS could extract Bax from mitochondria. As shown in Fig. 3, 2% CHAPS was as efficient as 2% Triton X-100 in extracting Bax from the mitochondrial membrane of both control and apoptotic cells. This is an important control to ensure that we were not extracting and analyzing only a subpopulation of Bax from the mitochondria.



View larger version (61K):
[in this window]
[in a new window]
 
Fig. 3.   Extraction of Bax from mitochondrial membranes. Mitochondria isolated from control and apoptotic cells were treated with either 2% CHAPS or 2% Triton X-100. The samples were centrifuged at 100,000 × g for 30 min, and the soluble and pellet fractions (1 µg of total protein) were analyzed on SDS-PAGE and Western blot with anti-Bax antibodies. Mit., total mitochondria; Mit. Sup., solubilized fraction; Mit. pellet, nonsolubilized fraction. C, CHAPS; T, Triton X-100.

Bax Quaternary Structure in CHAPS Mitochondrial Extracts from Control and Apoptotic HeLa Cells-- Mitochondria were isolated by differential centrifugation from control and apoptotic HeLa cells, proteins were extracted with 2% CHAPS as described under "Materials and Methods," and the soluble mitochondrial extracts were analyzed on gel filtration. In the mitochondrial extract from control cells, Bax eluted in fractions 36-40. This corresponds to a molecular mass of 20,000 Da, which is close to the theoretical calculated molecular mass of monomeric Bax, 22,000 Da (Fig. 4A). In contrast, in the mitochondrial extract from cells where apoptosis had been induced by staurosporine treatment, Bax eluted mainly as large oligomers in fractions 20-28. Two peaks with estimated molecular masses of 260,000 and 96,000 Da were consistently detected (n = 9) (Fig. 4A). The amount of monomeric Bax eluting in fractions 36-38 varied between preparations and could depend on the percentage of cells that had entered apoptosis at the time of harvest. Identical results were obtained with a monoclonal anti-Bax antibody, confirming that the protein detected was indeed Bax (results not shown).



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Analysis of CHAPS mitochondrial extract from control and apoptotic HeLa cells by gel filtration on Superdex 200. A, mitochondria were isolated by differential centrifugation and treated with 2% CHAPS. Solubilized proteins were recovered by centrifugation at 100,000 × g for 30 min. 500 µl of the soluble fraction containing 2 mg of protein was loaded on a Superdex 200 column (16/60) equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, pH 7.5, and eluted at a flow rate of 1 ml/min. Fractions of 2 ml were collected, and every second fraction was analyzed by SDS-PAGE and Western blot with antibodies against Bax, Bak, Bcl-XL, VDAC, and ANT. B, mitochondria were isolated on a sucrose gradient and subsequently treated as described for A. Every second fraction from the gel filtration column was analyzed by Western blot with antibodies against Bax.

Western blot analysis with marker antibodies for various organelles showed that the mitochondria isolated by differential centrifugation was contaminated mainly by ER (Fig. 5). To ensure that the Bax oligomers were associated with the mitochondria, the mitochondrial fraction was further purified on a sucrose gradient; this purification step improved the purity of the preparation. The sucrose gradient-purified mitochondria confirmed the result; oligomeric Bax (fractions 20-28) was found in the mitochondrial extract from apoptotic cells, whereas monomeric Bax (fractions 36-40) was present in both apoptotic and control mitochondrial extracts (Fig. 4B).



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Purity of the mitochondria preparations. Samples of crude HeLa cell extract (C), mitochondria isolated by differential centrifugation (D), and mitochondria isolated by sucrose gradient (G) from control and apoptotic (staurosporine treated) cells corresponding to 1 µg of total protein were analyzed by SDS-PAGE and Western blot with antibodies against Bax, Hsp70 (mitochondria marker), calnexin (ER marker), Golgi 58-kDa protein (Golgi marker), and catalase (peroxisome marker).

In addition, inducing apoptosis by exposing HeLa cells to UV irradiation also induced oligomerization of Bax associated with the mitochondria. Similar to mitochondrial extract from staurosporine-treated cells, two peaks of Bax oligomers at fractions 20-22 (Mr 260,000) and fractions 26-28 (Mr 96,000) were detected on gel filtration (Fig. 6). Furthermore, we treated isolated HeLa mitochondria with 50 nM caspase 8-cleaved Bid for 30 min. The extract from the Bid-treated mitochondria contained the same Bax oligomers as mitochondria from staurosporine- or UV-treated HeLa cells (Fig. 6). Thus, inducing apoptosis by three different stimuli all resulted in Bax oligomerization.



View larger version (60K):
[in this window]
[in a new window]
 
Fig. 6.   The Bax oligomers. Oligomeric recombinant full-length Bax (F.L. Bax) and CHAPS-solubilized mitochondrial extracts from staurosporine-treated (Bax HeLa Staurosporine) and UV-irradiated HeLa cells and isolated HeLa mitochondria treated with 50 nM caspase 8-cut Bid were analyzed on a Superdex 200 column (16/60) equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, pH 7.5, and eluted at a flow rate of 1 ml/min. Fractions of 2 ml were collected and analyzed by SDS-PAGE and Western blot with antibodies against Bax. The top part of the figure shows the scanned profiles of the recombinant full-length Bax and Bax HeLa staurosporine Western blots.

Composition of the Bax Oligomers-- In addition to its interactions with Bcl-2 family members, Bax has also been reported to interact with other mitochondrial membrane proteins. Interactions with the outer mitochondrial membrane protein VDAC and the inner membrane protein ANT, both part of the permeability transition pore, have been reported (49, 50). To investigate whether the Bax oligomers contained these proteins, the fractions from the gel filtration column were analyzed for Bak, Bcl-XL, VDAC, and ANT (Fig. 4A).

Two major peaks of Bak were detected, eluting in fractions 24-26 and 30-32. A low amount was also present over a wide molecular weight range (fractions 14-32), which suggests various forms of oligomers and/or complexes. However, no difference in the distribution between control and apoptotic cells was detected. Thus, since the Bax oligomers are not present in the mitochondrial membrane of nonapoptotic cells, interactions between Bak and the Bax oligomers are unlikely. Bcl-XL was similarly detected over a large range (fractions 16-32) with a major peak in fractions 26-32. As for Bak, no difference between control and apoptotic cells was detected.

VDAC eluted after the Bax oligomers (fractions 20-28) as a sharp peak at fractions 30-32 (48,000 Da) in the mitochondrial extract from both control and apoptotic cells. ANT eluted before the Bax oligomers at fractions 14-16 (650,000 Da). No difference was detected between the control and apoptotic mitochondrial extracts. These results show that neither VDAC nor ANT is part of the Bax oligomers extracted from mitochondria of apoptotic cells.

The Bax Oligomers-- The elution profile of oligomeric recombinant Bax from the gel filtration column showed two peaks eluting at fractions 22-24 (Mr 160,000) and 27-29 (Mr 80,000) (Fig. 6). This indicates that recombinant Bax forms two distinct oligomers containing different numbers of monomeric units. It appears that the larger oligomer (160,000 Da) could be a dimer of the smaller oligomer (80,000 Da). In the mitochondrial extract from apoptotic HeLa cells, we also detected two Bax peaks, the first peak eluting at fractions 20-22 (Mr 260,000) and the second peak at fractions 26-28 (Mr 96,000) (Figs. 4 and 6). The Bax oligomers from apoptotic mitochondrial extracts eluted at higher molecular weights compared with the recombinant protein. This difference in apparent molecular weight might indicate that in the mitochondrial membrane the Bax oligomers form stable complexes with as yet unidentified proteins.

To further investigate the composition of the Bax oligomers, we overexpressed Bax fused to three different epitope tags (HA, Myc, and His) in HEK cells. Since overexpression of Bax induces apoptosis, the transfected cells were cultured in the presence of the caspase inhibitor ZVAD to prevent transfected cells from dying and thus selecting for nontransfected cells. We verified by Western blot that the tagged Bax was localized, like endogenous Bax, both in the cytosol and the mitochondria (Fig. 7A). Mitochondria were then isolated from transfected and untransfected HEK cells, membrane proteins were extracted with 2% CHAPS, and the extracts were analyzed on gel filtration. To the cytosol from the transfected cells, 2% CHAPS was added, and the samples were analyzed on gel filtration. In the mitochondrial extract from untransfected cells and in the cytosol from transfected cells, only Bax monomers were detected (Fig. 8). However, in the mitochondrial extract from transfected cells (apoptotic cells), Bax oligomers similar to those in staurosporine or UV-irradiated HeLa cells were detected (Fig. 8). The majority of Bax in the oligomers was endogenous untagged Bax; thus, with the anti-Bax antibodies we did not detect the upper band corresponding to HA- and Myc-tagged Bax. To ensure that the tagged proteins were part of the oligomers, we further analyzed the fractions of the mitochondria extract from the transfected cells for the presence of tagged Bax. Although the concentration of the tagged proteins was low, we detected all three tags in the fractions containing Bax oligomers, fractions 18-30 (Fig. 8). To further investigate the composition of the Bax oligomers, we performed cross-linking experiments on isolated mitochondria from the Bax-transfected cells as described under "Materials and Methods." Bax was subsequently immunoprecipitated with anti-His antibodies, and the precipitated sample was analyzed on Western blot with anti-Bax, anti-HA, and anti-Myc antibodies. As seen in Fig. 7B, Bax oligomers precipitated with anti-His antibodies were reactive to Bax, HA, and Myc antibodies. On the contrary, no immunoreactivity was detected with anti-VDAC antibodies. These results show that the Bax oligomers from mitochondria of apoptotic cells are composed of multiple Bax monomers and are not only Bax monomers in complex with other proteins. Bax oligomers were not detected in the cytosol (Fig. 7B). It has been shown that in unactivated monomeric Bax the N terminus is not exposed and not immunoreactive (46); this presumably explains why we did not precipitate the monomeric N-terminal His-tagged Bax in the cytosol. The molecular weights of the Bax-reactive bands in the mitochondrial extract were estimated, and the corresponding number of Bax molecules in the complexes were calculated (Fig. 7C). Bands corresponding to Bax mono-, di-, tri-, and tetramers were identified. Although higher molecular weight bands can be detected, the molecular weights cannot be estimated in this region of the SDS-PAGE separation. One band (Fig. 7C, band d) between a Bax trimer and tetramer could correspond to a complex with an unidentified protein of ~15 kDa.



View larger version (45K):
[in this window]
[in a new window]
 
Fig. 7.   Composition of the Bax oligomers. HEK cells were cotransfected with Bax tagged with HA, Myc, and His at the N terminus. A, samples of the cytosol and mitochondria fraction corresponding to 10 µg of total protein were analyzed on Western blot with antibodies against, Bax, HA, Myc, and His. B, cytosol and mitochondria were isolated and treated with the cross-linkers bis-(sulfosuccinimidyl)suberate and disuccinimidyl suberate. After cross-linking, mitochondrial proteins were solubilized, and Bax was immunoprecipitated with anti-His antibodies from the solubilized mitochondrial and the cytosolic fractions. The immunoprecipitated samples were analyzed by reducing SDS-PAGE and Western blot with anti-Bax, anti-HA, anti-Myc, and anti-VDAC antibodies. C, The molecular weights of the Bax-immunoreactive bands (a-e) were estimated, and the corresponding number of Bax molecules were calculated.



View larger version (44K):
[in this window]
[in a new window]
 
Fig. 8.   Analysis of CHAPS mitochondrial extract from HEK cells by gel filtration on Superdex 200. Mitochondria from untransfected HEK cells and HEK cells transfected with HA-, Myc-, and His-tagged Bax were isolated and treated with 2% CHAPS. Solubilized proteins were recovered by centrifugation at 100,000 × g for 30 min. 500 µl of the soluble fraction containing 2 mg of protein was loaded on a Superdex 200 column (16/60) equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, pH 7.5, and eluted at a flow rate of 1 ml/min. Fractions of 2 ml were collected, and every second fraction was analyzed by SDS-PAGE and Western blot with antibodies against Bax. The fractions from the transfected mitochondrial extract were in addition analyzed by antibodies against HA, Myc, and His. Two Bax-reactive bands were identified; the upper band corresponds to HA and Myc tagged Bax, and the lower band corresponds to endogenous and His-tagged Bax. The cytosol fraction from transfected cells was treated with 2% CHAPS and analyzed as the mitochondrial extracts with anti-Bax antibodies.

Bax Localization in the Mitochondria-- We have recently shown that Bid treatment of isolated HeLa mitochondria results in the insertion of Bax into the outer mitochondrial membrane (51). Here we investigated whether the change in Bax quaternary structure was required for integration into the mitochondrial membrane during apoptosis. We treated mitochondria from control and apoptotic cells with 0.1 M Na2CO3, pH 12, which solubilizes proteins attached to the membrane, whereas proteins integrated into the lipid membrane remain associated with the membrane fraction. After this treatment, the soluble (attached proteins) and the membrane fraction (integrated proteins) were analyzed by Western blot. We confirmed the findings by Eskes et al. (51) that in control cells Bax was only attached to the mitochondrial membrane, whereas in the apoptotic cells most of the protein was inserted into the membrane (Fig. 9A). Bak and Bcl-XL were integrated into the membrane in both control and apoptotic cells. As expected, the membrane protein VDAC was found to be integrated into the membrane in both samples. As shown in Fig. 4, mitochondria from apoptotic cells contained both monomeric and oligomeric Bax. We then investigated the nature of the quaternary structure of membrane-integrated Bax. As shown in Fig. 9B, membrane-integrated Bax was present as the oligomer. A low amount of monomeric Bax was detected in the sodium carbonate-washed mitochondrial pellet. However, this was also detected in the control cells and is presumably a contamination of attached protein that was not completely removed.



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 9.   Localization of Bax at the mitochondrial membrane. A, mitochondria from control and apoptotic HeLa cells were treated with 0.1 M Na2CO3, pH 12, on ice for 20 min. At the end of the incubation, the sample was centrifuged at 100,000 × g for 1 h. The supernatant, which contained mitochondrial attached proteins (Att), was saved, and CHAPS was added to a final concentration of 2%. The pellet was suspended in MB containing 2% CHAPS, incubated on ice for 1 h, sonicated, and centrifuged at 100,000 × g for 30 min. The second supernatant contained the solubilized inserted membrane proteins (Ins). The two solubilized samples were analyzed by SDS-PAGE and Western blot with antibodies against, Bax, Bak, Bcl-XL, and VDAC. B, 500 µl of the solubilized samples were loaded on a Superdex 200 column (16/60) equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, pH 7.5, and eluted at a flow rate of 1 ml/min. For each sample, the fractions corresponding to monomeric and oligomeric Bax were pooled and were analyzed by SDS-PAGE and Western blot with antibodies against Bax. Ins, inserted; Att, attached; M, monomer; O, oligomer. C, mitochondria from control and apoptotic HeLa cells overexpressing Bcl-2 were treated with 0.1 M Na2CO3, pH 12, on ice for 20 min. At the end of the incubation, the samples were centrifuged at 100,000 × g for 1 h. The supernatant, which contained mitochondrial attached proteins (Att), was saved, and CHAPS was added to a final concentration of 2%. The pellet was suspended in MB containing 2% CHAPS, incubated on ice for 1 h, sonicated, and centrifuged at 100,000 × g for 30 min. The second supernatant contained the solubilized inserted membrane proteins (Ins). The two solubilized samples were analyzed by SDS-PAGE and Western blot with antibodies against Bax and Bcl-2.

Bax Oligomerization Does Not Appear in Bcl-2-overexpressing Cells-- A HeLa cell line overexpressing Bcl-2 (HeLa-Bcl-2) is resistant to staurosporine-induced apoptosis (44). We treated these cells with staurosporine for 16 h and analyzed Bax associated with the mitochondria of treated and control cells. Both control and staurosporine-treated cells contained only Bax monomers. No Bax oligomers were detected in mitochondria isolated from staurosporine-treated cells (Fig. 10). Bcl-2 eluted in fractions 26-30 in both control and staurosporine-treated cells. No difference in the elution profiles of Bak, Bcl-XL, and VDAC was detected between control and apoptotic cells. To determine whether Bax had been inserted into the mitochondrial membrane in the staurosporine-treated cells, we treated the isolated mitochondria with sodium carbonate. As seen in Fig. 9C, the monomeric Bax was only found attached to the mitochondrial membrane; no Bax was inserted in the membrane of this staurosporine-treated cells. Bcl-2 was found to be inserted into the mitochondrial membranes from both control and staurosporine-treated cells (Fig. 9C).



View larger version (40K):
[in this window]
[in a new window]
 
Fig. 10.   Analysis of CHAPS mitochondrial extract from control and staurosporine-treated Bcl-2-overexpressing HeLa cells by gel filtration on Superdex 200. Mitochondria were isolated and treated with 2% CHAPS. Solubilized proteins were recovered by centrifugation at 100,000 × g for 30 min. 500 µl of the soluble fraction containing 2 mg of protein was loaded on a Superdex 200 column (16/60) equilibrated in 25 mM Hepes-NaOH, 300 mM NaCl, 0.2 mM DTT, 2% (w/v) CHAPS, pH 7.5, and eluted at a flow rate of 1 ml/min. Fractions of 2 ml were collected, and every second fraction was analyzed by SDS-PAGE and Western blot with antibodies against Bax, Bcl-2, Bak, Bcl-XL, and VDAC.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The release of cytochrome c from mitochondria has been shown to play a crucial role in many apoptotic signaling cascades through the activation of the downstream effector caspases (28). Several studies point to Bax as a trigger of cytochrome c release (29-31). Based on the ability of this protein to form channels in synthetic lipid membranes, several models have been proposed that would allow Bax to form a cytochrome c-conducting channel. Bax oligomerization and insertion in the outer mitochondrial membrane resulting in a "Bax-only" channel or hybrid channels formed by Bax binding to VDAC or ANT represent alternative possible mechanisms (52, 53). Thus, at the molecular level, it remains unclear how Bax triggers cytochrome c release.

Here, using gel filtration analysis and cross-linking, we show the formation of high molecular weight Bax oligomers in mitochondrial membranes of apoptotic cells. Previous cross-linking experiments of Bax in mitochondrial membranes, followed by immunoprecipitation and Western blot analysis, have revealed the existence of several Bax-immunoreactive bands, suggesting the presence of Bax oligomers (51, 54). The use of Bax fused to various tags allowed us, for the first time, to demonstrate the formation of Bax oligomers during apoptosis. A direct relationship between formation of large Bax oligomers and apoptosis was further demonstrated by gel filtration analysis. Analysis of membrane proteins requires solubilization with detergents. The choice of detergent is critical, since the protein quaternary structure and complex interactions may be affected by the detergent (55, 56). Hsu and Youle (48) have reported that cytosolic Bax from thymic cells displayed different conformational states that depended on the detergent to which they were exposed. That certain detergents induce significant conformational changes in Bax was shown in a recent publication by Suzuki et al. (33). In the study by Suzuki et al. (33), results from NMR experiments support the formation of large Bax oligomers. In agreement with these data, we found that Triton X-100, but not CHAPS, was able to trigger oligomerization of pure recombinant monomeric Bax (rBax) (41). Importantly, unlike Bax, Bcl-2 and Bcl-XL monomers did not oligomerize in the presence of various detergents, including Triton X-100 (41, 57). Indeed, as expected, when we extracted mitochondrial membrane proteins from control and apoptotic cells with Triton X-100, Bax consistently eluted on gel filtration chromatography as a high molecular weight oligomer. In fact, several proteins analyzed, including Bak, Bcl-XL, and a major component of the permeability transition pore, VDAC, that has been reported to interact with Bax, coeluted with Bax in a discrete peak corresponding to a molecular mass of 260,000 Da. However, the mitochondrial membrane protein Cox IV did not coelute with the 260,000-Da complexes, indicating that the extraction procedure did not induce a general protein aggregation or only a fragmentation of the mitochondrial membrane.

The fact that CHAPS does not trigger oligomerization of recombinant and cytosolic monomeric Bax indicated that CHAPS was a more appropriate detergent to study Bax oligomerization in mitochondria during apoptosis. Using this detergent, we found that while mitochondrial Bax from control cells eluted as a monomer on gel filtration, the protein from mitochondria of apoptotic cells consistently eluted as large molecular weight oligomers, which were distributed in two major peaks corresponding to masses of 260,000 and 96,000 Da. This Bax elution profile was obtained in mitochondrial extracts from HeLa cells undergoing apoptosis induced by either staurosporine or UV irradiation. Moreover, we found that the addition of caspase 8-cut Bid, a Bax activator, to mitochondria isolated from HeLa cells was able to trigger the formation of similar large molecular weight Bax oligomers. These data suggest that oligomerization of Bax and its ability to form large oligomers may be a phenomenon common to several apoptotic pathways involving Bax. The Bax oligomers were always tightly inserted in the mitochondrial membranes, and they were never detected in the cytosol, suggesting that they may form at or within the outer mitochondrial membrane. However, we cannot rule out the possibility that these large Bax oligomers may form outside of mitochondria and, once formed, rapidly insert into the outer mitochondrial membrane, preventing their cytosolic detection. This latter hypothesis would be consistent with earlier data showing that Bax translocate from the cytosol to mitochondria during apoptosis (58-60) and that enforced dimerization of Bax is accompanied by its insertion in the mitochondrial membrane (54). However, in the latter study, the Bax-enforced dimers failed to trigger cytochrome c release from mitochondria, suggesting that Bax dimers are not the active quaternary structure. A recent study shows that Bax is able to trigger the release of cytochrome c from liposome. The quaternary structure of the cytochrome c-conducting Bax channels was estimated to be a tetramer (42).

Interestingly, we found that in Bcl-2-overexpressing cells that are resistant to staurosporine-induced apoptosis (44), Bax oligomerization did not occur. This result is consistent with our previous data showing that Bcl-2 prevents the conformational change of Bax, which precedes its activation and membrane insertion (46, 51). In the Bcl-2-overexpressing cells, Bcl-2 was found both in the cytosol and inserted in the mitochondrial membrane. It is unclear which of these two Bcl-2 pools prevents the conformational change that Bax undergoes during apoptosis.

Recently, we have shown that soluble monomers of rBax isolated from E. coli in the absence of detergent fail to display channel activity in liposomes and are unable to trigger cytochrome c release from liver mitochondria (41). However, when rBax is extracted from E. coli membranes with CHAPS, it is recovered as oligomers. Importantly, these oligomers display channel activity, indicating that CHAPS extraction is compatible with the preservation of Bax activity (data not shown). Strikingly, when we analyzed pure rBax extracted from E. coli membranes with CHAPS or Triton X-100 by gel filtration, two oligomer populations of 160,000 and 80,000 Da were detected. The significantly higher molecular mass of the Bax oligomers from mitochondrial membranes compared with the rBax oligomers suggests either a difference in the number of Bax subunits composing the oligomers or an association with other mitochondrial proteins.

In addition, we used gel filtration to examine the mitochondrial membrane extracts for the presence of other Bcl-2 family members (Bak, Bcl-XL, Bcl-2) as well as for VDAC and ANT. We observed that neither VDAC nor ANT copurified with Bax. Moreover, VDAC and ANT were eluted in different fractions. This result is consistent with previous data that showed that when ANT was extracted with CHAPS it was recovered bound to cyclophilin D alone, whereas in Triton X-100 extracts, the complex contained an equimolar amount of VDAC (61, 62). Since there is the possibility that, in the presence of CHAPS, interactions between Bax, ANT, and VDAC do not withstand the extraction procedure, we cannot exclude the possibility that these proteins interact within membranes. However, in contrast to previous results (49, 50), we have never been able to demonstrate such interactions by cross-linking experiments (51) or by immunoprecipitation (Fig. 7B and data not shown). These data suggest that even within membranes, interactions between Bax and ANT or Bax and VDAC may be weak or transient or, alternatively, that only minor amounts of these proteins interact with each other at any one time.

It is important to note that, in contrast to Bax, the quaternary structures of Bak, Bcl-XL, Bcl-2, VDAC, and ANT do not change significantly during apoptosis. All proteins appear to be part of large molecular weight complexes. Interactions between Bcl-2 and VDAC or Bcl-XL and Bak have previously been reported (49, 63, 64). The copurification of Bcl-2 with VDAC and of Bcl-XL with Bak is consistent with these data. However, copurification does not necessarily indicate direct interactions between the proteins.

In conclusion, we have demonstrated the formation of two high molecular weight Bax oligomers in mitochondrial membranes of cells undergoing apoptosis. The formation of these Bax oligomers involves a series of events, including a change in Bax conformation triggered by Bid or other "BH3-only" proteins (46) and insertion into the outer mitochondrial membrane (51). The exact protein composition of these oligomers now remains to be determined, although we already know that the core structure is composed of several Bax subunits. Moreover, it remains to be determined whether these large Bax oligomers constitute the cytochrome c-conducting channel in mitochondria.


    ACKNOWLEDGEMENTS

We thank Dr. Timothy Wells for encouragement and support, Drs. Amanda Proudfoot and Kinsey Maundrell for critical reading of the manuscript, Alena Hochmann for expert technical assistance, and Christopher Herbert for art work.


    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 41 22 706 9802; Fax: 41 22 794 6965; E-mail: bruno.antonsson@serono.com.

§ Present address: Dept. Biologie Cellulaire, University of Geneva, 30 qual E. Ansermet, 1211 Geneva 4, Switzerland.

Published, JBC Papers in Press, January 2, 2001, DOI 10.1074/jbc.M010810200


    ABBREVIATIONS

The abbreviations used are: CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate; PAGE, polyacrylamide gel electrophoresis; DTT, dithiothreitol; VDAC, voltage-dependent anion channel; ANT, adenosine nucleotide translocator; MB, mitochondrial buffer; HA, hemagglutinin; Mops, 4-morpholinepropanesulfonic acid; rBax, recombinant monomeric Bax.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Hengartner, M. O. (2000) Nature 407, 770-776[CrossRef][Medline] [Order article via Infotrieve]
2. Yang, E., and Korsmeyer, S. J. (1996) Blood 88, 386-401[Free Full Text]
3. Green, D. R., and Reed, J. C. (1998) Science 281, 1309-1312[Abstract/Free Full Text]
4. Kelekar, A., and Thompson, C. B. (1998) Trends Cell Biol. 8, 324-330[CrossRef][Medline] [Order article via Infotrieve]
5. Kroemer, G. (1997) Nat. Med. 3, 614-620[Medline] [Order article via Infotrieve]
6. Jacobson, M. D. (1997) Curr. Biol. 7, R277-R281[Medline] [Order article via Infotrieve]
7. Reed, J. C. (1997) Nature 387, 773-776[CrossRef][Medline] [Order article via Infotrieve]
8. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. (1993) Cell 74, 609-619[Medline] [Order article via Infotrieve]
9. Knudson, C. M., and Korsmeyer, S. J. (1997) Nat. Genet. 16, 358-363[Medline] [Order article via Infotrieve]
10. Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. (1994) Nature 369, 321-323[CrossRef][Medline] [Order article via Infotrieve]
11. Borner, C., Martinou, I., Mattmann, C., Irmler, M., Schaerer, E., Martinou, J.-C., and Tschopp, J. (1994) J. Cell Biol. 126, 1059-1068[Abstract]
12. Sedlak, T. W., Oltvai, Z. N., Yang, E., Wang, K., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7834-7838[Abstract]
13. Hsu, Y.-T., and Youle, R. J. (1997) J. Biol. Chem. 272, 13829-13834[Abstract/Free Full Text]
14. Chittenden, T., Flemington, C., Houghton, A. B., Ebb, R. G., Gallo, G. J., Elangovan, B., Chinnadurai, G., and Lutz, R. J. (1995) EMBO J. 14, 733-736
15. Hunter, J. J., and Parslow, T. G. (1996) J. Biol. Chem. 271, 8521-8524[Abstract/Free Full Text]
16. Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L., and Korsmeyer, S. J. (1996) Genes Dev. 10, 2859-2869[Abstract]
17. Zha, J., Harada, H., Osipov, K., Jockel, J., Waksman, G., and Korsmeyer, S. J. (1997) J. Biol. Chem. 272, 24101-24104[Abstract/Free Full Text]
18. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W., and Reed, J. C. (1993) Cancer Res. 53, 4701-4714[Abstract]
19. Newmeyer, D. D., Farschon, D. M., and Reed, J. C. (1994) Cell 79, 353-364[Medline] [Order article via Infotrieve]
20. Kroemer, G. (1997) Cell Death Diff. 4, 443-456[CrossRef]
21. Bossy-Wetzel, E., Newmeyer, D. D., and Green, D. R. (1998) EMBO J. 17, 37-49[Abstract/Free Full Text]
22. Single, B., Leist, M., and Nicotera, P. (1998) Cell Death Diff. 5, 1001-1003[CrossRef][Medline] [Order article via Infotrieve]
23. Kohler, C., Gahm, A., Noma, T., Nakazawa, A., Orrenius, S., and Zhivotovsky, B. (1999) FEBS letter 447, 10-12[CrossRef][Medline] [Order article via Infotrieve]
24. Lorenzo, H. K., Susin, S. A., Penninger, J., and Kroemer, G. (1999) Cell Death Diff. 6, 516-524[CrossRef][Medline] [Order article via Infotrieve]
25. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000) Cell 102, 33-42[Medline] [Order article via Infotrieve]
26. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. (2000) Cell 102, 43-53[Medline] [Order article via Infotrieve]
27. Goldstein, J. C., Waterhouse, N. J., Juin, P., Evan, G. I., and Green, D. R. (2000) Nat. Cell Biol. 2, 156-162[CrossRef][Medline] [Order article via Infotrieve]
28. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479-489[Medline] [Order article via Infotrieve]
29. Rosse, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., and Borner, C. (1998) Nature 391, 496-499[CrossRef][Medline] [Order article via Infotrieve]
30. Eskes, R., Antonsson, B., Osen-Sand, A., Montessuit, S., Richter, C., Sadoul, R., Mazzei, G., Nichols, A., and Martinou, J.-C. (1998) J. Cell Biol. 143, 217-224[Abstract/Free Full Text]
31. Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4997-5002[Abstract/Free Full Text]
32. Finucane, D. M., Bossy-Wetzel, E., Waterhouse, N. J., Cotter, T. G., and Green, D. R. (1999) J. Biol. Chem. 274, 2225-2233[Abstract/Free Full Text]
33. Suzuki, M., Youle, R. J., and Tjandra, N. (2000) Cell 103, 645-654[Medline] [Order article via Infotrieve]
34. Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., Ng, S.-C., and Fesik, S. W. (1996) Nature 381, 335-341[CrossRef][Medline] [Order article via Infotrieve]
35. Chou, J. J., Li, H., Salvesen, G. S., Yuan, J., and Wagner, G. (1999) Cell 96, 615-624[Medline] [Order article via Infotrieve]
36. McDonnell, J. M., Fushman, D., Milliman, C. L., Korsmeyer, S. J., and Cowburn, D. (1999) Cell 96, 625-634[Medline] [Order article via Infotrieve]
37. Minn, A. J., Velez, P., Schendoe, S. L., Liang, H., Muchmore, S. W., Fesik, S. W., Fill, M., and Thompson, C. B. (1997) Nature 385, 353-357[CrossRef][Medline] [Order article via Infotrieve]
38. Schendel, S. L., Xie, Z., Montal, M. O., Matsuyama, S., Montal, M., and Reed, J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5113-5118[Abstract/Free Full Text]
39. Antonsson, B., Conti, F., Ciavatta, A. M., Montessuit, S., Lewis, S., Martinou, I., Bernasconi, L., Bernard, A., Mermod, J.-C., Mazzei, G., Maundrell, K., Gambale, F., Sadoul, R., and Martinou, J.-C. (1997) Science 277, 370-372[Abstract/Free Full Text]
40. Schlesinger, P. H., Gross, A., Yin, X.-M., Yamamoto, K., Saito, M., Waksman, G., and Korsmeyer, S. L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11357-11362[Abstract/Free Full Text]
41. Antonsson, B., Montessuit, S., Lauper, S., Eskes, R., and Martinou, J.-C. (2000) Biochem. J. 345, 271-278[CrossRef][Medline] [Order article via Infotrieve]
42. Saito, M., Korsmeyer, S. J., and Schlesinger, P. H. (2000) Nat. Cell Biol. 2, 553-555[CrossRef][Medline] [Order article via Infotrieve]
43. Rojo, M., and Wallimann, T. (1994) Biochim. Biophys. Acta 1187, 360-367[Medline] [Order article via Infotrieve]
44. Estoppey, S., Rodriguez, I., Sadoul, R., and Martinou, J.-C. (1997) Cell Death Differ. 4, 34-38[CrossRef]
45. Montessuit, S., Mazzei, G., Magnenat, E., and Antonsson, B. (1999) Protein Expression Purif. 15, 202-206[CrossRef][Medline] [Order article via Infotrieve]
46. Desagher, S., Osen-Sand, A, Nichols, A., Eskes, R., Montessuit, S., Lauper, S., Maundrell, K., Antonsson, B., and Martinou, J-C. (1999) J. Cell Biol. 144, 891-901[Abstract/Free Full Text]
47. Wood, D. E., Thomas, A., Devi, L. A., Berman, Y., Beavis, R. C., Reed, J. C., and Newcomb, E. W. (1998) Oncogene 17, 1069-1078[CrossRef][Medline] [Order article via Infotrieve]
48. Hsu, Y.-T., and Youle, R. J. (1998) J. Biol. Chem. 273, 10777-10783[Abstract/Free Full Text]
49. Shimizu, S., Narita, M., and Tsujimoto, Y. (1999) Nature 399, 483-487[CrossRef][Medline] [Order article via Infotrieve]
50. Marzo, I., Brenner, C., Zamzami, N., Jurgensmeier, J. M., Susin, S. A., Vieira, H. L. A., Prevost, M.-C., Xie, Z., Matsuyama, S., Reed, J. C., and Kroemer, G. (1998) Science 281, 2027-2031[Abstract/Free Full Text]
51. Eskes, R., Desagher, S., Antonsson, B., and Martinou, J.-C. (2000) Mol. Cell. Biol. 20, 929-935[Abstract/Free Full Text]
52. Vander Heiden, M. G., and Thompson, C. B. (1999) Nat. Cell Biol. 1, E209-E215[CrossRef][Medline] [Order article via Infotrieve]
53. Martinou, J.-C., Desagher, S., and Antonsson, B. (2000) Nat. Cell Biol. 2, E41-E43[CrossRef][Medline] [Order article via Infotrieve]
54. Gross, A., Jockel, J., Wie, M. C., and Korsmeyer, S. L. (1998) EMBO J. 17, 3878-3885[Abstract/Free Full Text]
55. Helenius, A., and Simons, K. (1975) Biochim. Biophys. Acta 415, 29-79[Medline] [Order article via Infotrieve]
56. Newby, A. C., Chrambach, A., and Bailyes, E. M. (1982) Techniques in Lipid and Membrane Biochemistry , pp. 1-22, Elsevier/North-Holland, Amsterdam
57. Conus, S., Kaufmann, T., Fellay, I., Otter, I., Rosse, T., and Borner, C. (2000) EMBO J. 19, 1534-1544[Abstract/Free Full Text]
58. Hsu, Y.-T., Wolter, K. G., and Youle, R. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3668-3672[Abstract/Free Full Text]
59. Wolter, K. G., Hsu, Y. T., Smith, C. L., Nechushtan, A., Xi, X. G., and Youle, R. J. (1997) J. Cell Biol. 139, 1281-1292[Abstract/Free Full Text]
60. Goping, I. S., Gross, A., Lavoie, J. N., Nguyen, M., Jemmerson, R., Roth, K., Korsmeyer, S. J., and Shore, G. C. (1998) J. Cell Biol. 143, 207-215[Abstract/Free Full Text]
61. Crompton, M., Virji, S., and Ward, J. M. (1998) Eur. J. Biochem. 258, 729-735[Abstract]
62. Woodfield, K., Ruck, A., Brdiczka, D., and Halestrap, A. P. (1998) Biochem. J. 336, 287-290[Medline] [Order article via Infotrieve]
63. Griffiths, G. J., Dubrez, L., Morgan, C. P., Jones, N. A., Whitehouse, J., Corfe, B. M., Dive, C., and Hickman, J. A. (1999) J. Cell Biol. 144, 903-914[Abstract/Free Full Text]
64. Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., Thompson, C. B., and Fesik, S. W. (1997) Science 275, 983-986[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.